c-Kit (V559D)

KIT · Variant type: point · HGVS: p.V559D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Nintedanib	100.0%	0.0%	90.23
2	Avapritinib	100.0%	0.0%	97.73
3	Ponatinib	99.6%	0.4%	78.23
4	Tivozanib	99.0%	1.0%	92.42
5	Dasatinib	98.7%	1.3%	87.97
6	Ripretinib	98.6%	1.4%	92.95
7	Cabozantinib	98.5%	1.5%	92.73
8	Erdafitinib	98.1%	1.9%	95.71
9	Regorafenib	97.8%	2.2%	95.99
10	Sorafenib	97.5%	2.5%	96.72
11	Brigatinib	96.7%	3.3%	82.96
12	Pralsetinib	96.6%	3.4%	93.43
13	Axitinib	96.2%	3.8%	93.23
14	Nilotinib	95.5%	4.5%	96.49
15	Selpercatinib	94.6%	5.4%	96.72
16	Bosutinib	94.5%	5.5%	87.22
17	Pacritinib	94.1%	5.9%	88.64
18	Apatinib	94.0%	6.0%	97.73
19	Fostamatinib	92.7%	7.3%	96.74
20	Gilteritinib	91.0%	9.0%	88.97
21	Umbralisib	89.6%	10.4%	98.74
22	Fedratinib	88.4%	11.6%	96.21
23	Imatinib	88.1%	11.9%	99.00
24	Quizartinib	87.7%	12.3%	99.50
25	Alectinib	86.9%	13.1%	95.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Nintedanib	100.0%	—	—
Avapritinib	100.0%	—	—
Ponatinib	99.6%	—	—
Tivozanib	99.0%	—	—
Dasatinib	98.7%	—	—
Ripretinib	98.6%	—	—
Cabozantinib	98.5%	—	—
Erdafitinib	98.1%	—	—
Regorafenib	97.8%	—	—
Sorafenib	97.5%	—	—
Brigatinib	96.7%	—	—
Pralsetinib	96.6%	—	—
Axitinib	96.2%	—	—
Nilotinib	95.5%	—	—
Selpercatinib	94.6%	—	—
Bosutinib	94.5%	—	—
Pacritinib	94.1%	—	—
Apatinib	94.0%	—	—
Fostamatinib	92.7%	—	—
Gilteritinib	91.0%	—	—
Umbralisib	89.6%	—	—
Fedratinib	88.4%	—	—
Imatinib	88.1%	—	—
Quizartinib	87.7%	—	—
Alectinib	86.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms